Literature DB >> 11490001

Characterization of the active sites in decay-accelerating factor.

L A Kuttner-Kondo1, L Mitchell, D E Hourcade, M E Medof.   

Abstract

Decay-accelerating factor (DAF) is a complement regulator that dissociates autologous C3 convertases, which assemble on self cell surfaces. Its activity resides in the last three of its four complement control protein repeats (CCP2-4). Previous modeling on the nuclear magnetic resonance structure of CCP15-16 in the serum C3 convertase regulator factor H proposed a positively charged surface area on CCP2 extending into CCP3, and hydrophobic moieties between CCPs 2 and 3 as being primary convertase-interactive sites. To map the residues providing for the activity of DAF, we analyzed the functions of 31 primarily alanine substitution mutants based in part on this model. Replacing R69, R96, R100, and K127 in the positively charged CCP2-3 groove or hydrophobic F148 and L171 in CCP3 markedly impaired the function of DAF in both activation pathways. Significantly, mutations of K126 and F169 and of R206 and R212 in downstream CCP4 selectively reduced alternative pathway activity without affecting classical pathway activity. Rhesus macaque DAF has all the above human critical residues except for F169, which is an L, and its CCPs exhibited full activity against the human classical pathway C3 convertase. The recombinants whose function was preferentially impaired against the alternative pathway C3bBb compared with the classical pathway C4b2a were tested in classical pathway C5 convertase (C4b2a3b) assays. The effects on C4b2a and C4b2a3b were comparable, indicating that DAF functions similarly on the two enzymes. When CCP2-3 of DAF were oriented according to the crystal structure of CCP1-2 of membrane cofactor protein, the essential residues formed a contiguous region, suggesting a similar spatial relationship.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490001     DOI: 10.4049/jimmunol.167.4.2164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Complement regulation at the molecular level: the structure of decay-accelerating factor.

Authors:  P Lukacik; P Roversi; J White; D Esser; G P Smith; J Billington; P A Williams; P M Rudd; M R Wormald; D J Harvey; M D M Crispin; C M Radcliffe; R A Dwek; D J Evans; B P Morgan; R A G Smith; S M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

2.  Solution structure of a functionally active fragment of decay-accelerating factor.

Authors:  Stanislava Uhrinova; Feng Lin; Graeme Ball; Krystyna Bromek; Dusan Uhrin; M Edward Medof; Paul N Barlow
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

3.  Identification of a complement receptor 1 peptide for inhibition of immune hemolysis.

Authors:  Jin Yu; Susanne Heck; Asim Debnath; Karina Yazdanbakhsh
Journal:  Biochem Biophys Res Commun       Date:  2006-12-11       Impact factor: 3.575

Review 4.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.

Authors:  Joshua D Yoder; Javier O Cifuente; Jieyan Pan; Jeffrey M Bergelson; Susan Hafenstein
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

6.  Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli.

Authors:  Jennifer White; Petra Lukacik; Dirk Esser; Michael Steward; Naomi Giddings; Jeremy R Bright; Sarah J Fritchley; B Paul Morgan; Susan M Lea; Geoffrey P Smith; Richard A G Smith
Journal:  Protein Sci       Date:  2004-09       Impact factor: 6.725

7.  Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.

Authors:  Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Interaction of decay-accelerating factor with coxsackievirus B3.

Authors:  Susan Hafenstein; Valorie D Bowman; Paul R Chipman; Carol M Bator Kelly; Feng Lin; M Edward Medof; Michael G Rossmann
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

9.  Structure-function analysis of decay-accelerating factor: identification of residues important for binding of the Escherichia coli Dr adhesin and complement regulation.

Authors:  Rafia J Hasan; Edyta Pawelczyk; Petri T Urvil; Mathura S Venkatarajan; Pawel Goluszko; Jozef Kur; Rangaraj Selvarangan; Stella Nowicki; Werner A Braun; Bogdan J Nowicki
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  DAF in diabetic patients is subject to glycation/inactivation at its active site residues.

Authors:  Rudolf Flückiger; Enzo Cocuzzi; Ram H Nagaraj; Menachem Shoham; Timothy S Kern; M Edward Medof
Journal:  Mol Immunol       Date:  2017-09-05       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.